At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 107 enrolled
Drug / intervention
Bepreve +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating Bepreve, Placebo, and 1 other intervention for Conjunctivitis, Allergic. Completed, enrolled 107 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartFeb 2007
Primary CompletionJul 2007
TodayJul 2026
First PostedJan 19, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 19.5 years ago
Interventions
Beprevedrug
sterile ophthalmic solution
Placebodrug
sterile ophthalmic solution
Bepotastine Besilatedrug
sterile ophthalmic solution